Thermo Fisher Acquires Affinity BioReagents | GenomeWeb
NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it has acquired privately held antibody maker Affinity BioReagents for an undisclosed amount.
 
Golden, Colo.-based Affinity makes monoclonal and polyclonal antibodies, peptides, proteins, and other reagents. The firm, which offers more than 35,000 reagents, also provides recombinant proteins and custom antibody-production services, said Thermo Fisher.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.